Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Cell Biochem. 2013 Feb;114(2):435–447. doi: 10.1002/jcb.24383

Figure 6. ET receptor antagonism increases p-Ser1177 eNOS levels and NO in lambs acutely exposed to increased pulmonary blood flow.

Figure 6

Figure 6

Figure 6

Figure 6

PBF was acutely increased in 4-week old lambs in the absence (vehicle-treated) or presence of the ET receptor antagonist tezosentan (0.5mg/kg/hr). Lung biopsies were taken before (Pre) and 4h after (Post), the increase in PBF. Lysates (40μg) prepared from these samples were subjected to Western blot analysis and probed with anti-pSer1177- or anti-pThr495-eNOS antibodies. For normalization, duplicate samples were run and blotted, then probed with an antibody for total eNOS. In vehicle-treated lambs, pSer1177 eNOS levels decreased after 4h of increased PBF; whereas, in tezosentan-treated lambs pSer1177 eNOS levels increased (A). In vehicle-treated lambs, pThr495 eNOS levels increased after 4h of increased PBF; whereas, in tezosentan-treated lambs pThr495 eNOS levels decreased (B). The changes in phosphorylation corresponded with a reduction in NOx levels after 4h of increased PBF in vehicle-treated lambs, but an increase in NOX levels in tezosentan-treated lambs (C). No changes in either ETA or ETB receptor protein levels were observed (D-G). Data are mean ± SEM; n =4-5. *P <0.05 vs. pre shunt opening, †P<0.05 vs. vehicle-treated post.